WebNSW Health. Jan 2024 - Sep 20241 year 9 months. Sydney, Australia. Following my PhD, I first worked as a Clinical Trials Coordinator at … Web25 mei 2024 · The monarchE trial with abemaciclib enrolled patients with HR +, HER2 - node-positive EBC plus clinicopathological features suggesting a high risk of recurrence: ≥4 positive axillary lymph nodes (ALNs) or 1–3 positive ALNs and at least one of the following: tumor size ≥5 cm; histological grade 3; or Ki-67 ≥20% [ 8 ].
JPM Free Full-Text Feasibility of Adjuvant Treatment with ...
Web25 mei 2024 · Shared insight on the monarchE trial, which studied adjuvant abemaciclib in patients with HR+, HER2- high-risk early breast cancer. EP: 1. Molecular Testing Platforms in Breast Cancer EP: 2.... Web15 feb. 2024 · Improving adjuvant therapy for patients with high-risk disease is an important need. Trial design: monarchE (NCT03155997) is a multicenter, randomized, … hscc hastings
Abstract OT3-05-05: MonarchE: A randomized, open-label, phase …
Web4 jan. 2024 · The monarchE study is the first phase 3 trial that prospectively investigated Ki-67 as a biomarker for incorporating abemaciclib, a CDK4/6 inhibitor in the adjuvant setting. 6,11,12 The trial used the Agilent immunohistochemistry (IHC) assay and a standardized scoring algorithm to centralize the process of reporting Ki-67. 13 Patients … Web10 dec. 2024 · The global, phase III, monarchE trial randomly assigned 5,637 patients deemed at high risk for recurrence to adjuvant endocrine therapy for at least 5 years, with or without abemaciclib for 2 years. High risk was defined by a compilation of clinical and pathologic factors including nodal status, tumor size, grade, and Ki67 level. Web22 mrt. 2024 · In monarchE, abemaciclib plus endocrine therapy (ET) as adjuvant treatment of hormone receptor-positive, human epidermal growth factor 2-negative, high-risk, early breast cancer (EBC) demonstrated a clinically meaningful improvement in invasive disease-free survival versus ET alone. Detailed safety analyses conducted at a median follow-up … hobby lobby in north little rock